G1 Therapeutics & Pepper Bio have entered into a global licensing agreement (except the Asia-Pacific region) for lerociclib, entering into P-II clinical evaluations, covering all indications excl. some radioprotectant applications
Under the agreement, G1 is entitled to receive a mid-single-digit millions as upfront in 12mos., up to $135M as development & commercial milestones for up to 3 indications plus a double-digit royalty on lerociclib’s total annual net sales
Furthermore, Pepper Bio obtains exclusive global rights (excl. the Asia-Pacific region) to develop, manufacture & commercialize lerociclib covering all indications excl. some radioprotectant applications whereas license across the Asia-Pacific region has been granted to Genor Biopharma
Ref: G1 Therapeutics | Image: G1 Therapeutics
Related News:- G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
